USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: LIGOCYTE PHARMACEUTICALS, INC.
City: BOZEMAN
State: MT
Zip+4: 59718 0683
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (406) 585-2733

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,485,761.00 5
SBIR Phase II $2,041,726.00 2
STTR Phase I $205,728.00 1

Award List:

FOOD TEST FOR VEROTOXIN E COLI TO PREVENT INFECTIONS

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $76,274.00

RATIONAL DESIGN OF ADHESION BLOCKING ANTIINFLAMMATORIES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nagy, Jon O
Award Amount: $100,000.00

FOOD TEST FOR VEROTOXIN E COLI TO PREVENT INFECTIONS

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $747,372.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jon O. Nagy
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jon O. Nagy
Award Amount: $1,294,354.00

TUBERCLE BACILLI BINDING TO HOST CELLS: VACCINE DESIGN

Award Year / Program / Phase: 2002 / STTR / Phase I
Agency: HHS
Research Institution: MONTANA STATE UNIVERSITY
Principal Investigator: Luanne Hallstoodley
Award Amount: $205,728.00
RI Contact: N/A
Abstract:
Three million people die each year from tuberculosis (TB) in spite of the use of the existing anti-mycobacterial antibiotics and the BCG vaccine. Clearly, a better vaccine and better ways to treat TB are needed. The purpose of this STTR Phase I feasibility study is to evaluate Mycobacterium… More

GROUP B STREPTOCOCCAL PEPTIDE MIMETIC VACCINE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Pati M. Glee
Award Amount: $580,839.00
Abstract:
Group B streptococcus (GBS) causes invasive infections of newborns, pregnant women and adults with underlying medical conditions, such as diabetes or cancer. Despite antibiotic treatment, estimated case fatality rates of 5-20% in neonates and 15-32% in adults establish the prevention of GBS… More

Anthrax Vaccine Formulations Combining PA/Spore Epitopes

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Aiyappa M. Palecanda
Award Amount: $728,648.00
Abstract:
DESCRIPTION (provided by applicant): Pulmonary anthrax, a rare but extremely severe form of anthrax, is initiated by phagocytosis of Bacillus anthracis spores by alveolar macrophages (AMs). The current, Protective Antigen (PA) based, vaccine requires several boosts, is reactogenic and its efficacy,… More